Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.

Ther Adv Hematol · 2022 · PMC9726852 · PMID 36505885

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Long-term, NTD responders showed a trend toward decreasing EPO levels [ Figure 2(a) ].

also in 53,322 other papers

a decreasing trendno p-value reported

Reticulocyte levels in NTD erythroid responders, after an initial rise from baseline, showed a decreasing trend, whereas in nonresponders, the rising trend lasted throughout the base study and extension phase [ Figure 2(c) ].

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.